Tegretol Tegretol -XR WARNINGS
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Therapeutic Class Brand Name P a Status Generic
P A Therapeutic Class Brand Name Status Generic Name Strength Form Absorbable Sulfonamides AZULFIDINE SULFASALAZINE 250MG/5ML ORAL SUSP Absorbable Sulfonamides AZULFIDINE SULFASALAZINE 500MG TABLET Absorbable Sulfonamides AZULFIDINE SULFASALAZINE 500MG TABLET DR Absorbable Sulfonamides BACTRIM DS SULFAMETHOXAZOLE/TRIMETHO 800-160MG TABLET Absorbable Sulfonamides GANTRISIN SULFISOXAZOLE 500MG TABLET Absorbable Sulfonamides GANTRISIN SULFISOXAZOLE ACETYL 500MG/5ML ORAL SUSP Absorbable Sulfonamides GANTRISIN SULFISOXAZOLE ACETYL 500MG/5ML SYRUP Absorbable Sulfonamides SEPTRA SULFAMETHOXAZOLE/TRIMETHO 200-40MG/5 ORAL SUSP Absorbable Sulfonamides SEPTRA SULFAMETHOXAZOLE/TRIMETHO 400-80MG TABLET Absorbable Sulfonamides SULFADIAZINE SULFADIAZINE 500MG TABLET ACE Inhibitor/Calcium Channel Blocker Combination LOTREL AMLODIPINE BESYLATE/BENAZ 10-20MG CAPSULE ACE Inhibitor/Calcium Channel Blocker Combination LOTREL AMLODIPINE BESYLATE/BENAZ 2.5-10MG CAPSULE ACE Inhibitor/Calcium Channel Blocker Combination LOTREL AMLODIPINE BESYLATE/BENAZ 5-10MG CAPSULE ACE Inhibitor/Calcium Channel Blocker Combination LOTREL AMLODIPINE BESYLATE/BENAZ 5-20MG CAPSULE P A Therapeutic Class Brand Name Status Generic Name Strength Form ACE Inhibitor/Calcium Channel Blocker Combination LOTREL AMLODIPINE BESYLATE/BENAZ 5-40MG CAPSULE ACE Inhibitor/Calcium Channel Blocker Combination LOTREL AMLODIPINE BESYLATE/BENAZ 10-40MG CAPSULE Acne Agents, Systemic ACCUTANE ISOTRETINOIN 10MG CAPSULE Acne Agents, Systemic ACCUTANE ISOTRETINOIN 20MG CAPSULE Acne Agents, Systemic ACCUTANE -
Investigating the Influence of Polymers on Supersaturated
Page 1 of 45 Molecular Pharmaceutics 1 2 3 4 5 6 7 Investigating the Influence of Polymers on 8 9 10 11 12 Supersaturated Flufenamic Acid Cocrystal Solutions 13 14 15 16 1 1 2 2 1 17 Minshan Guo , Ke Wang , Noel Hamill , Keith Lorimer and Mingzhong Li * 18 19 20 1School of pharmacy, De Montfort University, Leicester, UK 21 22 23 2Almac Science, Seagoe Industrial Estate, Craigavon, UK 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 ACS Paragon Plus Environment 1 Molecular Pharmaceutics Page 2 of 45 1 2 3 4 5 6 7 Table of contents graphic 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 ACS Paragon Plus Environment 2 Page 3 of 45 Molecular Pharmaceutics 1 2 3 Abstract 4 5 6 7 The development of enabling formulations is a key stage when demonstrating the effectiveness 8 9 10 of pharmaceutical cocrystals to maximize the oral bioavailability for poorly water soluble drugs. 11 12 Inhibition of drug crystallization from a supersaturated cocrystal solution through a fundamental 13 14 understanding of the nucleation and crystal growth is important. In this study, the influence of 15 16 17 the three polymers of polyethylene glycol (PEG), polyvinylpyrrolidone (PVP) and a copolymer 18 19 of N-vinly-2-pyrrodidone (60%) and vinyl acetate (40%) (PVP-VA) on the flufenamic acid 20 21 22 (FFA) crystallization from three different supersaturated solutions of the pure FFA and two 23 24 cocrystals of FFA-NIC CO and FFA-TP CO has been investigated by measuring nucleation 25 26 induction times and desupersaturation rates in the presence and absence of seed crystals. -
Optum Essential Health Benefits Enhanced Formulary PDL January
PENICILLINS ketorolac tromethamineQL GENERIC mefenamic acid amoxicillin/clavulanate potassium nabumetone amoxicillin/clavulanate potassium ER naproxen January 2016 ampicillin naproxen sodium ampicillin sodium naproxen sodium CR ESSENTIAL HEALTH BENEFITS ampicillin-sulbactam naproxen sodium ER ENHANCED PREFERRED DRUG LIST nafcillin sodium naproxen DR The Optum Preferred Drug List is a guide identifying oxacillin sodium oxaprozin preferred brand-name medicines within select penicillin G potassium piroxicam therapeutic categories. The Preferred Drug List may piperacillin sodium/ tazobactam sulindac not include all drugs covered by your prescription sodium tolmetin sodium drug benefit. Generic medicines are available within many of the therapeutic categories listed, in addition piperacillin sodium/tazobactam Fenoprofen Calcium sodium to categories not listed, and should be considered Meclofenamate Sodium piperacillin/tazobactam as the first line of prescribing. Tolmetin Sodium Amoxicillin/Clavulanate Potassium LOW COST GENERIC PREFERRED For benefit coverage or restrictions please check indomethacin your benefit plan document(s). This listing is revised Augmentin meloxicam periodically as new drugs and new prescribing LOW COST GENERIC naproxen kit information becomes available. It is recommended amoxicillin that you bring this list of medications when you or a dicloxacillin sodium CARDIOVASCULAR covered family member sees a physician or other penicillin v potassium ACE-INHIBITORS healthcare provider. GENERIC QUINOLONES captopril ANTI-INFECTIVES -
Effect of Felodipine Against Pilocarpine Induced Seizures in Rats
Int. J. Pharm. Sci. Rev. Res., 52(1), September - October 2018; Article No. 10, Pages: 54-60 ISSN 0976 – 044X Research Article Effect of Felodipine against Pilocarpine induced Seizures in Rats Osama Q. Fadheel 1, Faruk H. AL-Jawad 1, Waleed K. Abdulsahib 2, Haider F. Ghazi 3 1Pharmacology Department, College of Medicine, Al-Nahrain University, Baghdad, Iraq. 2Pharmacy department, Al- Farahidi University College, Baghdad, Iraq. 3Microbiology Department, College of Medicine, Al-Nahrain University, Iraq. *Corresponding author’s E-mail: [email protected] Received: 25-07-2018; Revised: 22-08-2018; Accepted: 05-09-2018. ABSTRACT Epilepsy is a standout amongst the most well-known genuine cerebrum issue, can happen at all ages. The examination was performed to investigate the conceivable antiepileptic impact of Felodipine against pilocarpine prompted seizure in male rats. The investigation did on forty male Wister rats similarly assigned to four gathering: (1) typical gathering (not got any medication). Gathering (2) negative control gathering (got just pilocarpine amid acceptance of seizure. Gathering (3) positive control gathering (Valproic corrosive gathering got 20 mg/kg orally twice every day). Gathering (4) Felodipine gathering (1 mg/kg got orally once every day). Rats of each gathering (aside from typical gathering) were infused intraperitoneal with pilocarpine hydrochloride (400 mg/kg) following 21 long stretches of tried medications organization orally. The mean beginning and term of seizure were resolved to assess the viability of tried medications and to contrast these impact and that of typical gathering and Valproic corrosive gathering. Additionally, neuroprotective impact (Neu N), NMDA receptor, Sodium diverts were estimated in all gatherings. -
Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany). -
1-(4-Amino-Cyclohexyl)
(19) & (11) EP 1 598 339 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: C07D 211/04 (2006.01) C07D 211/06 (2006.01) 24.06.2009 Bulletin 2009/26 C07D 235/24 (2006.01) C07D 413/04 (2006.01) C07D 235/26 (2006.01) C07D 401/04 (2006.01) (2006.01) (2006.01) (21) Application number: 05014116.7 C07D 401/06 C07D 403/04 C07D 403/06 (2006.01) A61K 31/44 (2006.01) A61K 31/48 (2006.01) A61K 31/415 (2006.01) (22) Date of filing: 18.04.2002 A61K 31/445 (2006.01) A61P 25/04 (2006.01) (54) 1-(4-AMINO-CYCLOHEXYL)-1,3-DIHYDRO-2H-BENZIMIDAZOLE-2-ONE DERIVATIVES AND RELATED COMPOUNDS AS NOCICEPTIN ANALOGS AND ORL1 LIGANDS FOR THE TREATMENT OF PAIN 1-(4-AMINO-CYCLOHEXYL)-1,3-DIHYDRO-2H-BENZIMIDAZOLE-2-ON DERIVATE UND VERWANDTE VERBINDUNGEN ALS NOCICEPTIN ANALOGE UND ORL1 LIGANDEN ZUR BEHANDLUNG VON SCHMERZ DERIVÉS DE LA 1-(4-AMINO-CYCLOHEXYL)-1,3-DIHYDRO-2H-BENZIMIDAZOLE-2-ONE ET COMPOSÉS SIMILAIRES POUR L’UTILISATION COMME ANALOGUES DU NOCICEPTIN ET LIGANDES DU ORL1 POUR LE TRAITEMENT DE LA DOULEUR (84) Designated Contracting States: • Victory, Sam AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU Oak Ridge, NC 27310 (US) MC NL PT SE TR • Whitehead, John Designated Extension States: Newtown, PA 18940 (US) AL LT LV MK RO SI (74) Representative: Maiwald, Walter (30) Priority: 18.04.2001 US 284666 P Maiwald Patentanwalts GmbH 18.04.2001 US 284667 P Elisenhof 18.04.2001 US 284668 P Elisenstrasse 3 18.04.2001 US 284669 P 80335 München (DE) (43) Date of publication of application: (56) References cited: 23.11.2005 Bulletin 2005/47 EP-A- 0 636 614 EP-A- 0 990 653 EP-A- 1 142 587 WO-A-00/06545 (62) Document number(s) of the earlier application(s) in WO-A-00/08013 WO-A-01/05770 accordance with Art. -
Dorset Medicines Advisory Group
DORSET CARDIOLOGY WORKING GROUP GUIDELINE FOR CALCIUM CHANNEL BLOCKERS IN HYPERTENSION SUMMARY The pan-Dorset cardiology working group continues to recommend the use of amlodipine (a third generation dihydropyridine calcium-channel blocker) as first choice calcium channel blocker on the pan-Dorset formulary for hypertension. Lercanidipine is second choice, lacidipine third choice and felodipine is fourth choice. This is due to preferable side effect profiles in terms of ankle oedema and relative costs of the preparations. Note: where angina is the primary indication or is a co-morbidity prescribers must check against the specific product characteristics (SPC) for an individual drug to confirm this is a licensed indication. N.B. Lacidipine and lercandipine are only licensed for use in hypertension. Chapter 02.06.02 CCBs section of the Formulary has undergone an evidence-based review. A comprehensive literature search was carried out on NHS Evidence, Medline, EMBASE, Cochrane Database, and UK Duets. This was for recent reviews or meta-analyses on calcium channel blockers from 2009 onwards (comparative efficacy and side effects) and randomised controlled trials (RCTs). REVIEW BACKGROUND Very little good quality evidence exists. No reviews, meta-analyses or RCTs were found covering all calcium channel blockers currently on the formulary. Another limitation was difficulty obtaining full text original papers for some of the references therefore having to use those from more obscure journals instead. Some discrepancies exist between classification of generations of dihydropyridine CCBs, depending upon the year of publication of the reference/authors’ interpretation. Dihydropyridine (DHP) CCBs tend to be more potent vasodilators than non-dihydropyridine (non-DHP) CCBs (diltiazem, verapamil), but the latter have greater inotropic effects. -
Module 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods
CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods Module 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods Copyright 2012 ViiV Healthcare and the GlaxoSmithKline group of companies. All rights reserved. Unauthorized copying or use of this information is prohibited. 1 CONFIDENTIAL 2.7.1 Summary of Biopharmaceutic Studies and Associated Analytical Methods TABLE OF CONTENTS PAGE ABBREVIATIONS ...........................................................................................................3 1. BACKGROUND AND OVERVIEW ...........................................................................4 1.1. Conclusions ..................................................................................................4 1.2. Formulation Development.............................................................................5 1.3. In Vitro Dissolution Data .............................................................................10 1.3.1. Comparative of 2 x 25 mg Clinical Tablets and 1 x 50 mg Clinical Tablets, Phase III Formulation.........................................10 1.3.2. Comparison of Phase III Clinical Image and Commercial Image Tablets..............................................................................13 1.4. Analytical Methods......................................................................................17 1.4.1. Validation.....................................................................................17 1.4.2. Summary of Within Study Quality -
Evaluation of Therapeutic Drug Monitoring (TDM) on Older Antiepileptic Medications
Available online a t www.scholarsresearchlibrary.com Scholars Research Library Der Pharmacia Lettre, 2015, 7 (2):243-250 (http://scholarsresearchlibrary.com/archive.html) ISSN 0975-5071 USA CODEN: DPLEB4 Evaluation of therapeutic drug monitoring (TDM) on older antiepileptic medications Dayana Nicholas* 1, Azmi Bin Sarriff 2, Tharmalingam Palanivelu 3, Kenneth Nelson 4 and Samson P. George 5 1Department of Clinical Pharmacy & Pharmacy Practice, Faculty of Pharmacy, AIMST University, Bedong, Kedah, Malaysia 2School of Pharmaceutical Sciences, Department of Clinical Pharmacy & Faculty of Pharmacy, University Sains Malaysia, Penang, Malaysia 3Consultant Physician and Head of Department, Department of Medicine, Hospital Sultan Abdhul Halim, Malaysia 4Department of Pharmacy Practice, Faculty of Pharmacy, Grace College of Pharmacy, Kerala, India 5Drug Information Centre, Karnataka State Pharmacy Council, Bangalore, Karnataka, India _____________________________________________________________________________________________ ABSTRACT The Prospective study was conducted to evaluate the measure of Therapeutic Drug Monitoring (TDM) services on conventional antiepileptic drugs (AEDs) in 160 epileptic patients’ data of children and adults with both genders was on AEDs. The study results have shown 66 patients (50.38%), under subtherapeutic range on single AEDs with phenytoin and Na.valproate. In 160 patients, 13 of 98 (13.54%) adult patients received co-medication and 3 of 62 (6.25%) children with co-medications. Overall average (Vd) for carbamazepine in adult and children patients was found to be 78.25L which was higher than Vd for phenytoin (35.12L) and Na.Valproate (11.73L). The overall mean of clearance (Cl) for phenytoin (35.59L/hr) was found to be the highest, followed by Carbamazepine (3.81L/hr) and Na.Valproate (0.40L/hr). -
Prevalence of Drug Interactions in Hospitalized Elderly Patients: a Systematic Review
Supplementary material Eur J Hosp Pharm Prevalence of drug interactions in hospitalized elderly patients: a systematic review Luciana Mello de Oliveira 1,2; Juliana do Amaral Carneiro Diel1; Alessandra Nunes3; Tatiane da Silva Dal Pizzol 1,2,3 1Programa de Pós-Graduação em Epidemiologia, Faculdade de Medicina, Universidade Federal do Rio Grande do Sul. 2Programa de Pós-Graduação em Assistência Farmacêutica, Faculdade de Farmácia, Universidade Federal do Rio Grande do Sul. 3Faculdade de Farmácia, Universidade Federal do Rio Grande do Sul. Corresponding author: Luciana Mello de Oliveira – [email protected] and Tatiane da Silva Dal Pizzol - [email protected] Supplementary Table 3: Number of patients with interaction, number of DDI per patient with at least one DDI, drugs or drug classes mostly involved with DDI and drug combinations mostly involved with DDI. In cases which prevalence were described, we reported the three drugs mostly involved with drug interactions or the three drug combinations (or drug classes) mostly involved with DDI. ACE: angiotensin-converting enzyme. NA: not available. NSAID: non-steroidal anti-inflammatory drugs. PPI: proton-pump inhibitors. # of patients with # of DDI per patient with First autor interactions interaction Drugs or drug classes mostly involved with DDI Drug combinations mostly involved with DDI Barak-Tsarfir O, et al (61) Unclear: around 56 patients NA NA NA Warfarin; digitoxin; prednisolone antithrombotic agents; non-steroidal anti- 70 (evaluated only serious or inflammatory agents; angiotensin converting enzyme Blix HS, et al (29) contraindicated DDI) NA inhibitors N/A Serious: chlorpromazine + promethazine; chlorpromazine + haloperidol; haloperidol + promethazine; diazepam + phenobarbital; risperidone + haloperidol; carbamazepine + ketoconazole; carbamazepine + chlorpromazine; haloperidol + ketoconazole; chlorpromazine + ketoconazole; chlorpromazine + sodium phosphate. -
Medication Guide Omeprazole Delayed-Release Capsules
MEDICATION GUIDE OMEPRAZOLE DELAYED-RELEASE CAPSULES, USP Read this Medication Guide before you start taking omeprazole delayed-release capsules and each time you get a refill. There may be new information. This information does not take the place of talking with your doctor about your medical condition or your treatment. What is the most important information I should know about omeprazole delayed-release capsules? Omeprazole delayed-release capsules may help your acid-related symptoms, but you could still have serious stomach problems. Talk with your doctor. Omeprazole delayed-release capsules can cause serious side effects, including: z Diarrhea. Omeprazole delayed-release capsules may increase your risk of getting severe diarrhea. This diarrhea may be caused by an infection (Clostridium difficile) in your intestines. Call your doctor right away if you have watery stool, stomach pain, and fever that does not go away. z Bone fractures. People who take multiple daily doses of proton pump inhibitor medicines for a long period of time (a year or longer) may have an increased risk of fractures of the hip, wrist, or spine. You should take omeprazole delayed-release capsules exactly as prescribed, at the lowest dose possible for your treatment and for the shortest time needed. Talk to your doctor about your risk of bone fracture if you take omeprazole delayed-release capsules. Omeprazole delayed-release capsules can have other serious side effects. See “What are the possible side effects of omeprazole delayed-release capsules?” What is omeprazole delayed-release capsule? Omeprazole delayed-release capsule is a prescription medicine called a proton pump inhibitor (PPI). -
Clinical and Biochemical Characteristics and Genotype – Phenotype Correlation in Finnish Variegate Porphyria Patients
European Journal of Human Genetics (2002) 10, 649 – 657 ª 2002 Nature Publishing Group All rights reserved 1018 – 4813/02 $25.00 www.nature.com/ejhg ARTICLE Clinical and biochemical characteristics and genotype – phenotype correlation in Finnish variegate porphyria patients Mikael von und zu Fraunberg*,1, Kaisa Timonen2, Pertti Mustajoki1 and Raili Kauppinen1 1Department of Medicine, Division of Endocrinology, University Central Hospital of Helsinki, Biomedicum Helsinki, Helsinki, Finland; 2Department of Dermatology, University Central Hospital of Helsinki, Biomedicum Helsinki, Helsinki, Finland Variegate porphyria (VP) is an inherited metabolic disease resulting from the partial deficiency of protoporphyrinogen oxidase, the penultimate enzyme in the heme biosynthetic pathway. We have evaluated the clinical and biochemical outcome of 103 Finnish VP patients diagnosed between 1966 and 2001. Fifty-two per cent of patients had experienced clinical symptoms: 40% had photosensitivity, 27% acute attacks and 14% both manifestations. The proportion of patients with acute attacks has decreased dramatically from 38 to 14% in patients diagnosed before and after 1980, whereas the prevalence of skin symptoms had decreased only subtly from 45 to 34%. We have studied the correlation between PPOX genotype and clinical outcome of 90 patients with the three most common Finnish mutations I12T, R152C and 338G?C. The patients with the I12T mutation experienced no photosensitivity and acute attacks were rare (8%). Therefore, the occurrence of photosensitivity was lower in the I12T group compared to the R152C group (P=0.001), whereas no significant differences between the R152C and 338G?C groups could be observed. Biochemical abnormalities were significantly milder suggesting a milder form of the disease in patients with the I12T mutation.